Results 191 to 200 of about 27,029 (300)

IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani   +22 more
wiley   +1 more source

Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome

open access: yesAnnals of the American Thoracic Society, 2017
David T. Huang   +15 more
semanticscholar   +1 more source

ON/OFF Phenomenon in 4‐Aminopyridine Therapy in Spinocerebellar Ataxia 27B: Therapeutic and Diagnostic Insights

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Chiara Caneda   +6 more
wiley   +1 more source

Ultrasound‐Confirmed Median Nerve Pseudoconduction Block due to Anatomical Variation

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Conduction block (CB) at non‐entrapment sites is an important electrodiagnostic (EDX) feature supporting acquired demyelinating neuropathies. However, anatomical variation may produce pseudoconduction block, mimicking true CB.
Yajing Ye   +2 more
wiley   +1 more source

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents

open access: yesJA Clinical Reports, 2019
Michiko Higashi   +2 more
doaj   +1 more source

Neuroprotective Effects of RNS60 in TDP‐43 Pathology‐Associated Amyotrophic Lateral Sclerosis

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction TDP‐43 pathology is broadly observed in the cerebral cortex of patients with amyotrophic lateral sclerosis (ALS). RNS60, an experimental treatment for acute ischemic stroke and ALS, enhanced mitochondrial biogenesis and function in other preclinical models.
Danny R. Vesevick   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy